Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Long-Term Deferred Tax: 2023-2024

  • Crinetics Pharmaceuticals' Long-Term Deferred Tax rose 49.75% to $291.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $291.5 million, marking a year-over-year increase of 49.75%. This contributed to the annual value of $291.5 million for FY2024, which is 49.75% up from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Long-Term Deferred Tax stood at $291.5 million for Q4 2024, which was up 49.75% from $194.7 million recorded in Q4 2023.
  • Crinetics Pharmaceuticals' 5-year Long-Term Deferred Tax high stood at $291.5 million for Q4 2024, and its period low was $194.7 million during Q4 2023.
  • Over the past 2 years, Crinetics Pharmaceuticals' median Long-Term Deferred Tax value was $243.1 million (recorded in 2023), while the average stood at $243.1 million.
  • Data for Crinetics Pharmaceuticals' Long-Term Deferred Tax shows a peak YoY skyrocketed of 49.75% (in 2024) over the last 5 years.
  • Quarterly analysis of 2 years shows Crinetics Pharmaceuticals' Long-Term Deferred Tax stood at $194.7 million in 2023, then skyrocketed by 49.75% to $291.5 million in 2024.